Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates
Clinical Pharmacology in Drug Development · 2026-04 · 15 (4)
DOI: 10.1002/cpdd.70059 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 19.04.2026. Verfasst von Ronilda D'Cunha und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Inc., North Chicago, IL, USA. Hauptthemen laut MEDLINE: Nuclear Receptor Subfamily 1, Group F, Member 3, Cytochrome P-450 Enzyme System. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This study aimed to characterize the effects of cedirogant, an inverse agonist of retinoic acid–related orphan receptor gamma thymus (RORγt), on activities of cytochrome P450 (CYP) enzymes in healthy adults. Twenty study participants received a single oral dose of the modified Cooperstown 5+1 cocktail CYP probe drugs alone without cedirogant (Period 1, midazolam on Day 1 and other CYP substrates on Day 2), and again following once‐daily dosing of 375 mg cedirogant (Period 2, cedirogant on Days 1‐18, midazolam on Day 13, and other CYP substrates on Day 14). Blood samples and 12‐hour urine samples were collected to measure the exposures of the CYP probe drugs and selected metabolites. The point estimates (90% confidence intervals) of the area under the plasma concentration–time curve from time 0 to infinity (AUC inf ) ratio with and without cedirogant co‐administration were 0.370 (0.325‐0.420) for midazolam (CYP3A), 1.161 (1.031‐1.307) for caffeine (CYP1A2), and 0.788 (0.761‐0.816) for S‐Warfarin (CYP2C9). The estimated ratios of plasma metabolite/parent AUC ratio for omeprazole (CYP2C19) and parent/metabolite molar urine recovery ratio for dextromethorphan (CYP2D6) with versus without cedirogant co‐administration were 2.115 (1.813‐2.467) and 0.951 (0.802‐1.128), respectively. Based on these findings, once‐daily administration of 375‐mg cedirogant showed moderate induction of CYP3A and CYP2C19, a weak effect on CYP2C9, and no clinically relevant effects on CYP1A2 or CYP2D6.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, AbbVie Inc., North Chicago, IL, USA.
- Discovery and Exploratory Statistics, AbbVie Inc., North Chicago, IL, USA.
- Immunology Clinical Development, AbbVie Inc., North Chicago, IL, USA.
- Global Patient Safety, AbbVie Inc., North Chicago, IL, USA.
- Regulated Bioanalysis, AbbVie Inc., North Chicago, IL, USA.
Zitieren
APA
D'Cunha, R., Qian, Y., Hao, S., Eccleston, J., Levy, G. F., Gannu, S., Rizzo, D. G., Liu, W., & Mohamed, M. F. (2026). Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates. Clinical Pharmacology in Drug Development, 15(4). https://doi.org/10.1002/cpdd.70059
Vancouver
D'Cunha R, Qian Y, Hao S, Eccleston J, Levy GF, Gannu S, et al. Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates. Clinical Pharmacology in Drug Development. 2026;15(4). doi:10.1002/cpdd.70059
BibTeX
@article{DCunha2026,
author = {D'Cunha, Ronilda and Qian, Yuli and Hao, Shuai and Eccleston, Jason and Levy, Gweneth F and Gannu, Shashikanth and Rizzo, David G and Liu, Wei and Mohamed, Mohamed-Eslam F},
title = {Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cpdd.70059}
}
EUVIMED